GlassScriptPhysician profile
Maribel Castillo
NPI 1760887541
$4,209.64
in general payments reported to CMS, 2019-2025
28 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $709 · 2023: $1,064 · 2024: $1,502 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,053.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $681.41 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $499.38 | 2021-2024 | |
| Insulet Corporation | $316.06 | 2022-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $313.04 | 2021-2024 | Airsupra |
| Medtronic, INC. | $292.09 | 2023-2024 | Minimed 780g, Corevalve Evolut R, Interstim |
| Dexcom, INC. | $272.32 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $245.58 | 2022-2024 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $126.72 | 2022-2025 | Gattex |
| Phathom Pharmaceuticals, INC. | $122.79 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $122.18 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biohaven Pharmaceutical Holding Company LTD. | $114.77 | 2022 | |
| Beta Bionics, INC. | $106.73 | 2023 | Ilet Bionic Pancreas |
| Alnylam Pharmaceuticals INC. | $106.10 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.33 | 2024 | Caplyta |
| Enterra Medical, INC. | $101.21 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $97.74 | 2021 | |
| Ascendis Pharma Endocrinology INC | $93.35 | 2023-2024 | |
| Genzyme Corporation | $82.32 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $77.67 | 2023 | Rexulti |
| Tandem Diabetes Care, INC. | $65.93 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.67 | 2021 | |
| Tolmar, INC. | $48.16 | 2023-2024 | |
| Medline Industries LP | $34.32 | 2024 | |
| Stryker Corporation | $34.22 | 2024 | Scopis Ent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.12 | 2023 | Xifaxan |
| Ucb, INC. | $24.54 | 2024 | Fintepla |
| Sanofi Pasteur INC. | $19.89 | 2023 | |
| Biomarin Pharmaceutical INC. | $19.00 | 2023 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribel Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.